<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18371">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867735</url>
  </required_header>
  <id_info>
    <org_study_id>CLKA651X2104</org_study_id>
    <nct_id>NCT02867735</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema</brief_title>
  <official_title>A Randomized, Single-masked, Sham-control, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema From Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (AMD), or Retinal Vein Occlusions (RVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of LKA651 in patients with macular edema from
      diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal
      vein occlusions (RVO)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Of participants with Adverse Events as a measure of Safety and Tolerability</measure>
    <time_frame>Day 1 through study completion</time_frame>
    <description>To evaluate the safety and tolerability of LKA651 by reviewing any adverse events after medical or ophthalmic examinations that are possibly or probably related to study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Single Dose of LKA651 - Area Under the Curve (AUC)</measure>
    <time_frame>Plasma samples were collected at Days 1,2,5,8,15,29,43,57,71,85</time_frame>
    <description>To evaluate the serum pharmacokinetic profile of LKA651 Measured by AUC(0-last) - Area under the plasma concentration time curve from time zero to the last quantifiable concentration-time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Single Dose of LKA651 - Cmax</measure>
    <time_frame>Plasma samples were collected at Days 1,2,5,8,15,29,43,57,71,85</time_frame>
    <description>To evaluate the serum pharmacokinetic profile of LKA651 Measured by Cmax - The maximum plasma concentration of study medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Macular Edema</condition>
  <condition>Diabetic Macular Edema (DME)</condition>
  <condition>Neovascular Age-related Macular Degeneration(AMD)</condition>
  <condition>Retinal Vein Occlusions(RVO)</condition>
  <arm_group>
    <arm_group_label>LKA651</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LKA651</intervention_name>
    <description>Interventional</description>
    <arm_group_label>LKA651</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Comparator</intervention_name>
    <arm_group_label>Sham Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients with macular edema with center involvement in at least one eye, including those
        with focal or diffuse DME, neovascular AMD, or RVO

        The ETDRS letter score in the study eye must be 60 letters or worse (approximate Snellen
        equivalent of 20/63)

        Vital signs as specified within the protocol

        Exclusion Criteria:

        -Proliferative diabetic retinopathy in the study eye, with the exception of tufts of
        neovascularization less than one disc area with no vitreous hemorrhage

        Patient, with type 1 or type 2 diabetes who have a hemoglobin A1C &gt; or = 12% at screening

        other ocular conditions as specified in the protocol

        systemic conditions as specified in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 12, 2016</lastchanged_date>
  <firstreceived_date>August 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>Diabetic Macular Edema (DME)</keyword>
  <keyword>Neovascular age-related Macular Degeneration(AMD)</keyword>
  <keyword>Retinal Vein Occlusions(RVO)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
